OKYO’s eye drop OK-101 has hit endpoints for ocular pain, tear film breakup time and conjunctival staining in Phase II, while demonstrating a placebo-like tolerability profile.

Having acquired Xiidra from Novartis and getting US approval of Miebo in 2023, B+L’s two-product dry eye franchise delivered 66% year-over-year growth during Q4 2023.

The PharmaMar subsidiary is the latest group to crash in a notoriously hard-to-treat disease, leaving Bausch + Lomb more firmly in command of the field.

An "uncontested market" in the neoadjuvant setting potentially awaits Sun’s partnered melanoma asset Nidlegy, while competition heats up for products like Cequa in the US. Scrip pieces together management commentary and analysts’ outlook on some of the key specialty therapies that India’s top-ranked drug maker is building out.